Press releases

5
Sep 2017
02:15 E.S.T.

Cellectis Reports Clinical Hold of UCART123 Studies

Read more
17
Aug 2017
20:30 E.S.T.

Cellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center

Read more
2
Aug 2017
20:30 E.S.T.

Cellectis Reports Financial Results for 2nd Quarter and First Six Months 2017

Read more
25
Jul 2017
20:01 E.S.T.

Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering

Read more
24
Jul 2017
20:30 E.S.T.

Cellectis Granted Patent for CRISPR Use in T-Cells

Read more
19
Jul 2017
22:54 E.S.T.

Calyxt Announces Pricing of $56.0 Million Initial Public Offering

Read more
10
Jul 2017
11:08 E.S.T.

Calyxt Announces Proposed Initial Public Offering of $100.0 Million

Read more
28
Jun 2017
20:30 E.S.T.

Cellectis Appoints Rainer Boehm, M.D. and Hervé Hoppenot to Board of Directors

Read more
27
Jun 2017
20:30 E.S.T.

First in Human Administration of UCART123 in Cellectis’ AML Phase I Clinical Trial at Weill Cornell Medicine, NewYork-Presbyterian Hospital

Read more
26
Jun 2017
20:30 E.S.T.

Cellectis S.A. Reports Results from Annual General Meeting Held on June 26, 2017

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US